These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 20412877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P.
    Vaccine; 2007 Jan 08; 25(4):659-63. PubMed ID: 17011678
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B, Kositanont U, Rittayamai N, Niyomthong P, Songserm T, Maranetra KN, Rattanasaengloet K, Nana A.
    Hum Vaccin Immunother; 2016 Jul 02; 12(7):1728-37. PubMed ID: 27153158
    [Abstract] [Full Text] [Related]

  • 5. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY.
    Vaccine; 2012 Oct 05; 30(45):6427-35. PubMed ID: 22910287
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC, Rock MT, Neuzil KM.
    Clin Infect Dis; 2010 May 15; 50(10):1331-8. PubMed ID: 20377407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ.
    J Med Virol; 2009 Apr 15; 81(4):722-7. PubMed ID: 19235853
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.
    Vaccine; 2014 May 01; 32(21):2507-17. PubMed ID: 24120672
    [Abstract] [Full Text] [Related]

  • 11. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.
    Chuaychoo B, Kositanont U, Niyomthong P, Rittayamai N, Srisuma S, Rattanasaengloet K, Wongsrisakunkaew W, Thongam J, Songserm T.
    Hum Vaccin Immunother; 2020 Jun 02; 16(6):1371-1379. PubMed ID: 31770051
    [Abstract] [Full Text] [Related]

  • 12. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 02; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 13. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
    Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, Kudo Y.
    Vaccine; 2008 May 23; 26(22):2700-5. PubMed ID: 18436353
    [Abstract] [Full Text] [Related]

  • 14. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 23; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 15. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.
    Vaccine; 2008 Dec 02; 26(51):6614-9. PubMed ID: 18930093
    [Abstract] [Full Text] [Related]

  • 16. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 17. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of intradermal influenza vaccine in children.
    Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N.
    Vaccine; 2011 Oct 13; 29(44):7606-10. PubMed ID: 21855592
    [Abstract] [Full Text] [Related]

  • 19. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G.
    N Engl J Med; 2004 Nov 25; 351(22):2286-94. PubMed ID: 15525713
    [Abstract] [Full Text] [Related]

  • 20. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.
    Vaccine; 2009 Dec 09; 27(52):7304-12. PubMed ID: 19849996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.